NDATOPICALAEROSOL, FOAM
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
6/8 — Strong
ENSTILAR (calcipotriene and betamethasone dipropionate) by Leo Pharma is d3 analog and betamethasone dipropionate as a synthetic corticosteroid. First approved in 2015.
Drug data last refreshed 16h ago · AI intelligence enriched 20h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENSTILAR is a topical aerosol foam combining calcipotriene (vitamin D3 analog) and betamethasone dipropionate (synthetic corticosteroid) for the treatment of plaque psoriasis. The exact mechanisms of action remain incompletely understood, though both agents are known to have pharmacologic effects on psoriatic lesions. This fixed-dose combination leverages dual mechanisms to improve efficacy and convenience for patients.
$0.008BPart D
Peak5.2 years to LOEENSTILAR is in peak lifecycle with modest Part D spending (~$8M, 4,633 claims in 2023), indicating a stable niche product with limited growth upside and likely smaller commercial team size.
Mechanism of Action
D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis are unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
Started Nov 2021
6 enrolled
Nail Psoriasis
Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails
Started Oct 2020
11 enrolled
Nail Psoriasis
Taltz in Combination With Enstilar for Psoriasis
Started Apr 2020
25 enrolled
Psoriasis
Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
Started Mar 2019
10 enrolled
Nail Psoriasis
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Started Jan 2019
30 enrolled
Psoriasis
Worked on ENSTILAR at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.